) is aiming for a big slice of the multibillion-dollar diabetes market with a new pill, approved by U.S. authorities on Friday, that caters for patients with an aversion to needles.
The company built its position as the world’s biggest insulin maker on the back of injectable drugs, but now aims to transform the market with a first-of-its-kind tablet version of its semaglutide drug. “We have only worked with around 25% of the patients so far and we see it as a breakthrough because we can now also address the tablet-based market,” chief scientific officer Mads Krogsgaard Thomsen told Reuters on Monday.
Better than an iPad? I don’t have diabetes though
Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação: